Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Concomitant medication, comorbidity and survival in patients with breast cancer.
Dumas E, Grandal Rejo B, Gougis P, Houzard S, Abécassis J, Jochum F, Marande B, Ballesta A, Del Nery E, Dubois T, Alsafadi S, Asselain B, Latouche A, Espie M, Laas E, Coussy F, Bouchez C, Pierga JY, Le Bihan-Benjamin C, Bousquet PJ, Hotton J, Azencott CA, Reyal F, Hamy AS. Dumas E, et al. Among authors: alsafadi s. Nat Commun. 2024 Apr 5;15(1):2966. doi: 10.1038/s41467-024-47002-3. Nat Commun. 2024. PMID: 38580683 Free PMC article.
Corrigendum to "Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma" [Eur J Cancer 126 (2020) 93-103].
Decaudin D, Dit Leitz EF, Nemati F, Tarin M, Naguez A, Zerara M, Marande B, Vivet-Noguer R, Halilovic E, Fabre C, Jochemsen A, Roman-Roman S, Alsafadi S. Decaudin D, et al. Among authors: alsafadi s. Eur J Cancer. 2023 May;184:199. doi: 10.1016/j.ejca.2023.02.004. Epub 2023 Mar 1. Eur J Cancer. 2023. PMID: 36868971 Free article. No abstract available.
Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma.
Decaudin D, Frisch Dit Leitz E, Nemati F, Tarin M, Naguez A, Zerara M, Marande B, Vivet-Noguer R, Halilovic E, Fabre C, Jochemsen A, Roman-Roman S, Alsafadi S. Decaudin D, et al. Among authors: alsafadi s. Eur J Cancer. 2020 Feb;126:93-103. doi: 10.1016/j.ejca.2019.12.012. Epub 2020 Jan 9. Eur J Cancer. 2020. PMID: 31927215 Free article.
FAK Inhibitor-Based Combinations with MEK or PKC Inhibitors Trigger Synergistic Antitumor Effects in Uveal Melanoma.
Tarin M, Némati F, Decaudin D, Canbezdi C, Marande B, Silva L, Derrien H, Jochemsen AG, Gardrat S, Piperno-Neumann S, Rodrigues M, Mariani P, Cassoux N, Stern MH, Roman-Roman S, Alsafadi S. Tarin M, et al. Among authors: alsafadi s. Cancers (Basel). 2023 Apr 13;15(8):2280. doi: 10.3390/cancers15082280. Cancers (Basel). 2023. PMID: 37190207 Free PMC article.
Cytidine analogs are synthetic lethal with base excision repair default due to MBD4 deficiency.
Chabot T, Nemati F, Herbette A, Demeyer A, Dayot S, Ganier O, Alsafadi S, Gardrat S, Mariani P, Luporsi M, Corbé M, Servois V, Cassoux N, Decaudin D, Roman SR, Del Nery E, Piperno-Neumann S, Stern MH, Rodrigues M. Chabot T, et al. Among authors: alsafadi s. NPJ Precis Oncol. 2022 Nov 2;6(1):81. doi: 10.1038/s41698-022-00326-z. NPJ Precis Oncol. 2022. PMID: 36323843 Free PMC article.
Evolutionary Routes in Metastatic Uveal Melanomas Depend on MBD4 Alterations.
Rodrigues M, Mobuchon L, Houy A, Alsafadi S, Baulande S, Mariani O, Marande B, Ait Rais K, Van der Kooij MK, Kapiteijn E, Gassama S, Gardrat S, Barnhill RL, Servois V, Dendale R, Putterman M, Tick S, Piperno-Neumann S, Cassoux N, Pierron G, Waterfall JJ, Roman-Roman S, Mariani P, Stern MH. Rodrigues M, et al. Among authors: alsafadi s. Clin Cancer Res. 2019 Sep 15;25(18):5513-5524. doi: 10.1158/1078-0432.CCR-19-1215. Epub 2019 Jun 21. Clin Cancer Res. 2019. PMID: 31227496
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.
Quek L, David MD, Kennedy A, Metzner M, Amatangelo M, Shih A, Stoilova B, Quivoron C, Heiblig M, Willekens C, Saada V, Alsafadi S, Vijayabaskar MS, Peniket A, Bernard OA, Agresta S, Yen K, MacBeth K, Stein E, Vassiliou GS, Levine R, De Botton S, Thakurta A, Penard-Lacronique V, Vyas P. Quek L, et al. Among authors: alsafadi s. Nat Med. 2018 Aug;24(8):1167-1177. doi: 10.1038/s41591-018-0115-6. Epub 2018 Jul 16. Nat Med. 2018. PMID: 30013198 Free PMC article.
SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response.
Bland P, Saville H, Wai PT, Curnow L, Muirhead G, Nieminuszczy J, Ravindran N, John MB, Hedayat S, Barker HE, Wright J, Yu L, Mavrommati I, Read A, Peck B, Allen M, Gazinska P, Pemberton HN, Gulati A, Nash S, Noor F, Guppy N, Roxanis I, Pratt G, Oldreive C, Stankovic T, Barlow S, Kalirai H, Coupland SE, Broderick R, Alsafadi S, Houy A, Stern MH, Pettit S, Choudhary JS, Haider S, Niedzwiedz W, Lord CJ, Natrajan R. Bland P, et al. Among authors: alsafadi s. Nat Genet. 2023 Aug;55(8):1311-1323. doi: 10.1038/s41588-023-01460-5. Epub 2023 Jul 31. Nat Genet. 2023. PMID: 37524790 Free PMC article.
36 results